News of Note—Heartflow's noninvasive CAD test gets coverage in California, Alabama

Here's Friday's medtech news of note.

> Anthem Blue Cross Blue Shield, Blue Shield of California, and Blue Cross and Blue Shield of Alabama have issued a positive medical policy for Heartflow’s noninvasive coronary artery disease test, the Heartflow FFRct Analysis, which uses CT images to create a 3D model of a patient’s coronary arteries. Release

> Thermo Fisher set up a consortium in Europe to push the adoption of next-generation sequencing clinical research panels to help identify biomarkers associated with cancer immunotherapy. Release

> Hologic is rolling out its Brevera breast biopsy system, the first to combine tissue acquisition, real-time imaging, sample verification and advanced postbiopsy handling in one system. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Baxter teams up with healthcare incubator Matter on products and technology based on patient-driven innovation. Release

> Abbott won reimbursement for its FreeStyle Libre glucose-monitoring system in Japan. Release

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Exact Sciences received an FDA breakthrough designation for its liver cancer blood test as it finalized its $2.8 billion merger with Genomic Health.